Please assess the completion status of the following clinical trial:

Trial Title: Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is determined to be hypertensive~Exclusion Criteria:~* Participant has a history of severe or symptomatic hypertension~* Participant has history of heart failure, rhythm disturbance or cardiomyopathy, or obstructive valvular disease~* Participant has started taking hypertensive medications within the past 30 days~* Participant has a known sensitivity to losartan or history of angioneurotic edema

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Losartan potassium 0.1 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
- Losartan potassium 0.3 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
- Losartan potassium 0.7 to 1.4 mg/kg (Type: EXPERIMENTAL): Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved

Based on this trial design, predict the completion outcome and termination type (if applicable).